Opinion
Video
Examining the Need for Updated Guidelines for Uncomplicated UTIs
Panelists discuss how uncomplicated urinary tract infections (UTIs) are typically managed with empiric short-course antibiotics based on local resistance patterns while identifying significant gaps in the outdated 2010 Infectious Diseases Society of America (IDSA) guidelines, including insufficient guidance on emerging resistance trends, limited recommendations for alternative therapies, inadequate consideration of patient-specific factors, absence of antimicrobial stewardship protocols, and minimal direction on prevention strategies for recurrent infections.
Video Player is loading.
Video content above is prompted by the following:
- Provide a brief overview of how uncomplicated UTIs are typically managed. What gaps exist in the current IDSA guidelines for uncomplicated UTI, which were last updated in 2010?
Related Videos
Experts Spotlight Lasting Innovations From the COVID-19 Pandemic
Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?
Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
Emerging Therapeutic Areas for Bispecific Antibodies
Payer and Reimbursement Considerations for Bispecific Therapies
Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration
Comparing Standard-of-Care Antibiotics for Uncomplicated UTIs
Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy
Optimizing Bispecific Antibody Administration With EHR and Technology Solutions
Overcoming Access Challenges
Related Content
